(Thyroid Cancer) Is Selpercatinib Effective?
(Thyroid Cancer) Is Selpercatinib Effective?
Medical Supporter — Informationshinweis
Dieser Artikel ist eine Zusammenfassung internationaler medizinischer Informationen und stellt keine medizinische Beratung dar; er ersetzt nicht die Diagnose oder den Behandlungsplan Ihres behandelnden Arztes. Die dargestellten Informationen stammen aus öffentlichen Veröffentlichungen und offiziellen Angaben führender japanischer medizinischer Einrichtungen; Eignung und Wirkung einer Therapie sind individuell und müssen von einem qualifizierten Arzt beurteilt werden.
(Thyroid Cancer) Is Selpercatinib Effective?
- November 26, 2019
- Read time: 2 minutes
From September 27 to October 1, 2019, at the European Society for Medical Oncology conference in Barcelona, Lori J. Wirth presented "Efficacy, Safety, and RET Mutation-Positive Thyroid Cancer Cohort Analysis Results of Oral RET Inhibitor Selpercatinib (LOXO-292) Monotherapy in Previously Treated Solid Tumor Patients from the LIBRETTO-001 Phase 1/2 Trial."
The LIBRETTO-001 Phase 1/2 trial evaluates selpercatinib (LOXO-292) monotherapy in solid tumor patients with prior multiple treatments. The primary endpoint is objective response rate, with secondary endpoints including duration of response, progression-free survival, and overall survival.
The cohort analysis results for RET mutation-positive thyroid and medullary thyroid cancer were: thyroid cancer patients (N=26) achieved a 62% objective response rate as the primary endpoint; medullary thyroid cancer patients (N=226) achieved a 56% objective response rate as the primary endpoint.
Regarding safety, adverse events confirmed in ≥15% of patients (including other solid tumor patients) included thirst, diarrhea, hypertension, ALT elevation, and AST elevation—most were Grade 1 or 2 adverse events. The discontinuation rate due to adverse events was 1.7% (N=9 patients).
Based on the LIBRETTO-001 trial results, Lori J. Wirth concluded: Previously treated RET mutation-positive thyroid cancer and medullary thyroid cancer patients treated with selpercatinib (LOXO-292) monotherapy demonstrate good objective response rates with acceptable tolerability to adverse events.
【Notice】 Medical Supporter's translations of overseas clinical trial data and pharmaceutical information are not intended to encourage participation in clinical trials or the use of new drugs. The translated materials are for reference only and are not clinical guidelines. Please consult with healthcare professionals—the original source information below is definitive.
Source: LOXO-292 Demonstrates Promising Anti-Tumour Activity in RET-Altered Thyroid Cancer [ESMO 2019 Oncology News]
#Thyroid Cancer #Selpercatinib
-
Clinical Trial Medications
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Phase 2 Trial Results. (Lung Cancer) HER2-Mutated Non-Small Cell Lung Cancer with Enhertu Effective? (Lung Cancer) Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Behandlung in Japan im Blick? Brauchen Sie Informationen und Unterstützung?
Wir helfen Ihnen, die für eine medizinische Reise nach Japan nötigen Informationen zu ordnen, kontaktieren japanische Einrichtungen und organisieren eine Zweitmeinungsberatung.Die Erstberatung ist kostenlos; ein Berater hilft Ihnen, die nächsten Schritte zu klären.
Figure 1
Figure 2
Figure 3
Figure 4